ReviewMolecular biology reports2026
Targeting pathological chemokines in CVD: the role of saffron on CCL2 and CXCL8.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, necessitating a deeper understanding of its underlying mechanisms and potential therapeutic interventions. This narrative review explores the pivotal role of chemokines, specifically CCL2 and CXCL8, in the pathogenesis of atherosclerosis and other cardiovascular disorders. Chemokines are critical mediators of inflammation, orchestrating the recruitment of immune cells to sites of vascular injury, thereby contributing to the progression of atherosclerotic plaques and endothelial dysfunction. The review further examines the therapeutic potential of saffron (Crocus sativus), a natural compound known for its anti-inflammatory and antioxidant properties, in modulating the activity of these pathological chemokines. Furthermore, we elucidate the molecular mechanisms by which saffron affects CCL2 and CXCL8 levels, including the inhibition of key inflammatory signaling pathways, reduction of oxidative stress, and modulation of microRNA expression. The findings suggest that saffron may offer a promising adjunctive therapy for managing CVDs by attenuating the inflammatory processes driven by chemokines. This review underscores the need for further research to validate saffron’s efficacy and explore its mechanisms of action in clinical settings, ultimately aiming to enhance therapeutic strategies for CVD management.
Indexed as
Identifiers
41733713What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.